Loading
Regorafenib delayed progression by almost four months compared with placebo in gastrointestinal stromal tumours resistant to both imatinib and sunitinib, giving patients a third line of targeted therapy.
Phase 3 placebo-controlled trial of 199 patients with metastatic or unresectable GIST after failure of imatinib and sunitinib randomised 2:1 to regorafenib 160 mg daily (three weeks on, one off) or placebo with crossover at progression.
Median progression-free survival was 4.8 versus 0.9 months (hazard ratio 0.27) with disease control in 53 versus 9 percent; hypertension, hand-foot skin reaction and diarrhoea were the main toxicities.
Regorafenib is the standard third-line treatment for GIST after imatinib and sunitinib.
Shares Imatinib-resistant GIST, Sunitinib, Imatinib, The Lancet.
Shares Imatinib-resistant GIST, Sunitinib, Imatinib.
Shares Imatinib-resistant GIST, Sunitinib.
Shares Sunitinib, The Lancet.
Shares Imatinib-resistant GIST, Sunitinib, Imatinib.
Shares Sunitinib, The Lancet.